November 30, 2021, 15:33
Listen to the news
Preliminary studies have shown a decrease in the effectiveness of antibody cocktails of the biotech company Regeneron Pharmaceuticals and the pharmaceutical company Eli Lilly against the new omicron coronavirus strain. This is reported by the newspaper The Wall Street Journal.
According to the publication, this may indicate the need to modify existing drugs against coronavirus infection in the event of widespread use of omicron.
Regeneron said it intends to find out how much the new strain reduces the effectiveness of their drug in the coming weeks after additional research. In case of confirmation of a significant decrease in the effectiveness of the drug, the company expects to begin clinical trials of other combinations of antibodies. Eli Lilly has also embarked on such research.
A new variant of coronavirus B.1.1.529, later dubbed omicron, was identified last week in South Africa. Subsequently, cases of infection with it were registered in many countries, including in a number of states of the European Union. World Health Organization (WHO) Chairman Frank Ulrich Montgomery expressed concern that the new strain could be as dangerous as the Ebola virus.
Tuesday, November 30, Russian President Vladimir Putin demanded from the government a new plan of action due to the spread of the omicron strain around the world.